methyl 2-isocyanato-3-methylbutyrate | 81428-12-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-isocyanato-3-methylbutyrate
• 英文别名: methyl 2-isocyanato-3-methylbutanoate；N-Carbonyl-DL-valin-methylester
• CAS: 81428-12-8
• 化学式: C₇H₁₁NO₃
• 分子量: 157.169
• InChiKey: JCVZXXSBCISMLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-isocyanato-3-methylbutyrate 在 三乙胺 、 三苯基膦 作用下， 以 四氯化碳 、 乙醚 为溶剂， 反应 9.0h， 生成 methyl 3-methyl-2-<(phenylcarbonimidoyl)amino>butyrate
  参考文献：
  名称：

  Joachims, Johannes C.; Rahman, Mohammed Abdur, Chemische Berichte, 1984, vol. 117, # 2, p. 502 - 516

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-缬氨酸甲酯盐酸盐 以 甲苯 为溶剂， 反应 5.0h， 生成 methyl 2-isocyanato-3-methylbutyrate
  参考文献：
  名称：

  Organosilicon synthesis of isocyanates: IV. Synthesis of isocyanates from aliphatic and alkylaromatic amino acid esters

  摘要：

  Treatment of an alcoholic suspension of amino acids with trimethylchlorosilane yielded phenylglycine, valine, beta-phenylalanine, and homovaline ester hydrochlorides. Their saccharin-catalyzed silylation with hexamethyldisilazane proceeds quantitatively and involves only one proton of the amino group. The best conversion of the amino acid esters to the corresponding isocyanates was achieved by phosgene treatment of their monosilyl urethanes, rather than of the silylated amino esters. Monosilyl urethanes are formed quantitatively by treatment of the amino acid ester hydrochlorides with the hexamethyldisilazane-CO2 system. The H-1 NMR spectra show that monosilyl urethanes derived from alpha- and beta-amino acid esters are characterized by intramolecular interaction of the silicon atom and the oxygen atom of the carboxy group.

  DOI：

  10.1134/s1070363207040135

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE MTOR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011029027A1

  公开（公告）日：2011-03-10

  Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

  公式I的化合物：以及其中R1、R2、R2a、R3、n、X和环B具有说明书中给出的含义的盐，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。
• Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease
  作者：Anushka C. Galasiti Kankanamalage、Yunjeong Kim、Athri D. Rathnayake、Kevin R. Alliston、Michelle M. Butler、Steven C. Cardinale、Terry L. Bowlin、William C. Groutas、Kyeong-Ok Chang

  DOI：10.1021/acs.jmedchem.7b00497

  日期：2017.7.27

  Ester and carbamate prodrugs of aldehyde bisulfite adduct inhibitors were synthesized in order to improve their pharmacokinetic and pharmacodynamic properties. The inhibitory activity of the compounds against norovirus 3C-like protease in enzyme and cell-based assays was determined. The ester and carbamate prodrugs displayed equivalent potency to those of the precursor aldehyde bisulfite adducts and

  醛亚硫酸氢盐加合物抑制剂的酯和氨基甲酸酯前药被合成，以改善其药代动力学和药效学性质。在酶和基于细胞的测定中，确定了化合物对诺如病毒3C样蛋白酶的抑制活性。酯和氨基甲酸酯前药显示出与前体醛亚硫酸氢盐加合物和前体醛相同的效力。此外，发现酯的裂解速率取决于烷基链长。产生的前药显示出低细胞毒性和令人满意的肝微粒体稳定性和血浆蛋白结合。
• [EN] NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX ANALOGUES 4-(PHÉNOXYMÉTHYL)-1,3-DIOXOLANE FONCTIONNALISÉS PRÉSENTANT UNE INHIBITION DU CYTOCHROME P450 ET LEUR PROCÉDÉ D'UTILISATION
  申请人：CORTENDO AB PUBL

  公开号：WO2014122530A1

  公开（公告）日：2014-08-14

  Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol that include metabolic syndrome, and any involving the overproduction of Cortisol.

  本发明实施例涉及4-(苯氧甲基)-1,3-二噁烷类似物及其药物组合物，在治疗与皮质醇过度产生相关的疾病方面具有疾病修饰作用，包括代谢综合征以及任何涉及皮质醇过度产生的疾病。
• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20030064962A1

  公开（公告）日：2003-04-03

  The present invention relates generally to a novel class of pyrimidinones of Formula (I): 1 that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及一种新型的嘧啶酮类化合物，具有如下式（I）所示的结构，这些化合物可用作丝氨酸蛋白酶抑制剂，更具体地作为丙型肝炎病毒NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物的方法。
• ISOCYANATE PRODUCTION METHOD
  申请人：ASAHI KASEI KABUSHIKI KAISHA

  公开号：US20200115327A1

  公开（公告）日：2020-04-16

  An isocyanate production method according to the present invention is a method in which an isocyanate is produced by subjecting a carbamate to thermal decomposition, and includes: a step of preparing a mixture liquid containing the carbamate, an inactive solvent and a polyisocyanate compound; a step of conducting a thermal decomposition reaction of the carbamate by continuously introducing the mixture liquid into a thermal decomposition reactor; a step of collecting a low-boiling decomposition product by continuously extracting the low-boiling decomposition product in a gaseous state from the reactor, the low-boiling decomposition product having a boiling point lower than the polyisocyanate compound; and a step of collecting a high-boiling component by continuously extracting, from the reactor, a liquid phase component which is not collected in a gaseous state at the step of collecting the low-boiling decomposition product.

  根据本发明的一种异氰酸酯生产方法是一种通过将氨基甲酸酯经受热分解而生产异氰酸酯的方法，包括：准备含有氨基甲酸酯、无活性溶剂和多异氰酸酯化合物的混合液的步骤；通过持续将混合液引入热分解反应器对氨基甲酸酯进行热分解反应的步骤；通过持续从反应器中以气态形式提取低沸点分解产物的步骤，所述低沸点分解产物的沸点低于多异氰酸酯化合物；通过从反应器中持续提取未在收集低沸点分解产物的步骤中以气态形式收集的液相组分的步骤来收集高沸点组分。